GlassScriptPhysician profile
Julie Crafton
NPI 1740333756
$1,912.20
in general payments reported to CMS, 2019-2025
24 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $141 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $382.58 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $291.34 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $174.46 | 2025 | |
| Abbvie INC. | $138.48 | 2025 | |
| Lilly USA, LLC | $137.72 | 2024-2025 | Zepbound, Mounjaro |
| Amgen INC. | $129.14 | 2024-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $87.00 | 2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $83.02 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $76.47 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $65.98 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.26 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.70 | 2025 | Xifaxan |
| Averitas Pharma INC. | $27.09 | 2025 | Qutenza |
| Supernus Pharmaceuticals, INC. | $26.60 | 2025 | Qelbree |
| Axsome Therapeutics, INC. | $25.44 | 2025 | Symbravo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.23 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $23.23 | 2025 | |
| Daiichi Sankyo INC. | $22.82 | 2025 | Injectafer |
| Corium, LLC | $21.76 | 2025 | Azstarys |
| Millicent US INC | $18.56 | 2025 | Intrarosa, Femlyv |
| Aimmune Therapeutics, INC. | $17.99 | 2025 | Zenpep |
| Ardelyx, INC. | $14.61 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $14.30 | 2025 | Capvaxive |
| Exact Sciences Corporation | $13.42 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Crafton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.